API | at9283

at9283 Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Now

Chemistry

SMILES: O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
InChIKey: LOLPPWBBNUVNQZ-UHFFFAOYSA-N
Mol. Mass: 381.44
ALogP: 2.07 Partition coefficient
ChEMBL Molecule:
at-9283

More Chemistry

Pharmacology

Mechanisms of Action:
- Aurora kinase A (Homo sapiens) ^UniProt
- Aurora kinase B (Homo sapiens) ^UniProt
- Tyrosine-protein kinase ABL1 (Homo sapiens) ^UniProt
- Tyrosine-protein kinase JAK2 (Homo sapiens) ^UniProt
- Tyrosine-protein kinase JAK3 (Homo sapiens) ^UniProt
- Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

1-cyclopropyl-3-(3-(5-morpholin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-pyrazol-4-yl)urea | at9283 | at 9283 | at-9283

Organizations (9)

Research & Development (9)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (9)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (9)

Leukemia (Phase 1)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1/Phase 2)

Leukemia, Myeloid, Acute (Phase 1/Phase 2)

Lymphoma, Non-Hodgkin (Phase 1)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 1/Phase 2)

Neoplasms (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)

Primary Myelofibrosis (Phase 1/Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 5
# of Trial Organizations: 9

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue